netFormulary Coventry and Warwickshire Area Prescribing Committee NHS
Formulary  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
08.01.05  Expand sub section  Other antineoplastic drugs
Cytotoxic Drug Aflibercept
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of metastatic colorectal cancer
Not recommended by NICE
 
Link  NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
   
Atezolizumab
View adult BNF View SPC online View childrens BNF
Formulary
Red SO

Locally or advanced urothelia cancer when cisplatin unsuitable

 
Link  NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer
Link  NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
   
Axitinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of advanced renal cell carcinoma
 
Link  NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
   
Cytotoxic Drug Cabaziltaxel
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of prostate cancer
 
   
Carfilzomib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
 
Link  NICE TA457: Carfilzomib for previously treated multiple myeloma
   
Ceritinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of non-small cell lung cancer
 
Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
   
Dabrafenib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of unresectable or metastatic melanoma with a BRAF V600 mutation
 
Link  NICETA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
   
Elotuzumab
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of multiple myeloma
 
   
Ibrutinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO

Treatment of chronic lymphocytic leukaemia & Waldenstrom's macroglobulinaemia

 
Link  NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Link  NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
   
Idelalisib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO

Treatment of chronic lymphocytic leukaemia

 
Link  NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
   
Ixazomib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO

Relapsed or refractory multiple myeloma

 
Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
   
Lenvatinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of renal and thyroid cancer
 
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
   
Necitumumab
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of lung cancer
 
   
Olaparib
Formulary
Red SO
Treatment of ovarian, fallopian tube or peritoneal cancer
 
Link  NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
   
Cytotoxic Drug Panitumumab
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of colorectal cancer
 
   
Panobinostat
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of multiple myeloma
 
   
Pembrolizumab
View adult BNF View SPC online View childrens BNF
Formulary
Red SO

Treatment of metastatic non-small-cell lung cancer & urothelial cancer

 
Link  NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
   
Ponatinib (Iclusig)
View adult BNF View SPC online View childrens BNF
Formulary
Red SO

Treatment of chronic myeloid leukaemia & acute lymphoblastic leukaemia

 
Link  NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia – guidance
   
Ramucirumab
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
 
Link  NICE TA378: Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
Link  NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
   
Ruxolitinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of myelofibrosis
 
Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
   
Talimogene laherparepvec
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of melanoma
 
   
Trametinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of melanoma
 
   
Venetoclax
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of chronic lymphocytic leukaemia
 
Link  NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
   
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Arsenic trioxide
Cytotoxic Drug Arsenic Trioxide
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
For induction of remission and consolidation of relapsed refractory acute promyelocytic leukaemia
 
Link  NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
   
08.01.05  Expand sub section  Bevacizumab
Bevacizumab
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of breast, renal cell, lung, colorectal, ovarian, fallopian tube, or peritoneal cancer
 
Link  NICE TA212: Colorectal cancer (metastatic) - bevacizumab
Link  NICE TA214: Breast Cancer with taxane
Link  NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Link  NICE TA263: Breast cancer with capecitabine
Link  NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Link  NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
   
08.01.05  Expand sub section  Bexarotene to top
Bexarotene
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of cutaneous T-cell lymphomas
 
   
08.01.05  Expand sub section  Bortezomib
Cytotoxic Drug Bortezomib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of multiple myeloma and mantle cell lymphoma
 
Link  NICE TA129: Multiple myeloma - bortezomib
Link  NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Link  NICE TA311: Multiple myeloma - bortezomib (induction therapy
Link  NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Link  NICE TA401: Leukaemia (chronic myeloid) - bosutinib
   
08.01.05  Expand sub section  Brentuximab vedotin
Brentuximab vedotin
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of relapsed or refractory CD30+ Hodgkin’s lymphoma and treatment of relapsed or refractory systemic anaplastic large cell lymphoma
 
Link  NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Link  NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
   
08.01.05  Expand sub section  Cetuximab
Cetuximab
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of head and neck cancer and colorectal cancer

 
Link  NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
Link  NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Link  NICE TA323: treating anaemia in people with cancer - cetuximab
Link  NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Link  NICE TA473: Head and neck cancer (squamous cell carcinoma) - cetuximab
   
08.01.05  Expand sub section  Crisantaspase
Asparaginase
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of acute lymphoblastic leukaemia
 
   
Crisantaspase
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of acute lymphoblastic leukaemia
 
   
08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
Cytotoxic Drug Dacarbazine
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of melanoma, sarcomas and Hodgkin's Disease
 
   
Cytotoxic Drug Temozolomide
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of glioblastoma multiforme and malignant glioma
 
Link  NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Link  NICE TA23: Brain cancer - temozolomide
   
08.01.05  Expand sub section  Erlotinib
Erlotinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of non-small-cell lung and pancreatic cancer 
Link  NICE TA162: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Link  NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
Link  NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
08.01.05  Expand sub section  Hydroxycarbamide
Cytotoxic Drug Hydroxycarbamide
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of chronic myeloid leukaemia, and cancer of the cervix
 
   
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
Ipilimumab
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of melanoma
 
Link  NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Link  NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
   
08.01.05  Expand sub section  Mitotane to top
Mitotane
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of adrenocortical carcinoma
 
   
08.01.05  Expand sub section  Panitumumab
08.01.05  Expand sub section  Pentostatin
Cytotoxic Drug Pentostatin
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of hairy cell leukaemia
 
   
08.01.05  Expand sub section  Platinum compounds
Cytotoxic Drug Carboplatin
(Platinum based)
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of advanced ovarian cancer and lung cancer
 
   
Cytotoxic Drug Cisplatin
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of testicular, lung, cervical, bladder, head and neck, and ovarian cancer
 
   
Cytotoxic Drug Oxaliplatin
View adult BNF View SPC online View childrens BNF
Formulary
Red SO

Treatment of colon and colorectal cancer

 
Link  NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
   
08.01.05  Expand sub section  Porfimer sodium and temoporfin
Porfimer Sodium
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Photodynamic therapy of lung and oesophageal cancer
 
   
Temoporfin
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Photodynamic therapy of head and neck cancer
 
   
08.01.05  Expand sub section  Procarbazine to top
Cytotoxic Drug Procarbazine
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
 
   
08.01.05  Expand sub section  Protein kinase inhibitors
Afatinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of Epidermal Growth Factor Receptor TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer with activating eGFR mutation(s)
 
Link  NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
   
Alectinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of lung cancer
 
   
Cabozantinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of renal and thyroid cancer
 
Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
   
Dasatinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of leukaemia
 
Link  NICE TA425: high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML)
Link  NICE TA426: for untreated chronic myeloid leukaemia
   
Everolimus
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of renal, breast and pancreatic cancer, renal angiomyelolipoma and subependymal giant cell astrocytoma
 
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Gefitinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of non-small cell lung cancer
 
Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
   
Cytotoxic Drug Imatinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of leukaemias, gastrointestinal stromal tumours, dermatofibrosarcoma protuberans, and myelodysplastic/myeloproliferative diseases
 
Link  NICE TA196: Gastrointestinal stromal tumours - imatinib (adjuvant): guidance
Link  NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
Link  NICE TA241: Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)
Link  NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA70: Leukaemia (chronic myeloid) - imatinib
Link  NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
   
Nilotinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of chronic myeloid leukaemia
 
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Nintedanib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of lung cancer
 
Link  NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
   
Osimertinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of lung cancer
 
   
Pazopanib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of renal cell carcinoma and soft tissue sarcoma
 
Link  NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib
   
Regorafenib (Stivarga® )
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment colorectal cancer and gastrointestinal stromal tumours

 
Link  NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
   
Sunitinib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of gastro-intestinal and pancreatic tumours and renal cell carcinoma
 
Link  NICE TA169: Renal cell carcinoma - sunitinib
Link  NICE TA178: Renal cell carcinoma
Link  NICE TA179: Gastrointestinal stromal tumours - sunitinib
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Cytotoxic Drug Temsirolimus
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of renal cell carcinoma and mantle cell lymphoma
 
Link  NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
   
Tivozanib (Fotivda)
View adult BNF View SPC online View childrens BNF
Formulary
Red SO

Treatment of advanced renal cell carcinoma

 
Link  NICE TA512: Tivozanib for treating advanced renal cell carcinoma
   
Cytotoxic Drug Vandetanib (Caprelsa)
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of thyroid cancer
 
   
Vemurafenib
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of melanoma
 
Link  NICE TA176: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
Link  NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
   
08.01.05  Expand sub section  Taxanes
Cytotoxic Drug Docetaxel
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of cancer



 
Link  NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Link  NICE TA109: Breast cancer (early) - docetaxel
   
Cytotoxic Drug Paclitaxel
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of breast, ovarian, lung and pancreatic cancer and Karposi's sarcoma



 
Link  NICE TA108: Breast cancer (early) - paclitaxel
Link  NICE TA55: Ovarian cancer - paclitaxel (review)
   
Cytotoxic Drug Paclitaxel - Albumin Bound Formulation
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of breast, lung and pancreatic cancer
 
Link  NICE TA476: Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer
   
08.01.05  Expand sub section  Topoisomerase I inhibitors
Cytotoxic Drug Irinotecan infusion
View adult BNF View SPC online View childrens BNF
Formulary
Red SO

Treatment of colorectal cancer

 
Link  NICE CG131: Colorectal cancer: diagnosis and management
   
Cytotoxic Drug Topotecan
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of ovarian, cervical and lung cancer
 
Link  NICE TA183: Cervical cancer (recurrent) - topotecan
Link  NICE TA184: Lung cancer (small-cell) - topotecan
Link  NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
08.01.05  Expand sub section  Trabectedin
Cytotoxic Drug Trabectedin
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of soft tissue sarcoma and ovarian cancer
 
   
08.01.05  Expand sub section  Trastuzumab to top
Cytotoxic Drug Pertuzumab with trastuzumab & docetaxel
View adult BNF View SPC online View childrens BNF
Formulary
Red SO

Treatment of HER2-postive breast cancer

 
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
   
Cytotoxic Drug Trastuzumab emtansine
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Treatment of breast, oesophageal and stomach cancer
 
Link  NICE TA235: Osteosarcoma - mifamurtide
   
08.01.05  Expand sub section  Tretinoin
Tretinoin
View adult BNF View SPC online View childrens BNF
Formulary
Red SO
Induction of remission in acute promyelocytic leukaemia
 
   
08.01.05  Expand sub section  Vismodegib
 ....
 Non Formulary Items
Bosutinib  (Bosulif®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Not Recommended
Treatment of adult patients with chronic phase,accelerated phase, and blast phase Philadelphia chromosome positive chronic myelogenous leukaemia previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options
 
Crizotinib

View adult BNF View SPC online View childrens BNF
Non Formulary
Not Recommended
Treatment of adults with previously treated anaplastic lymphoma kinase-positive advanced non-small cell lung cancer
Not recommended by NICE
Link  NICE TA296: Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene
 
Cytotoxic Drug  Irinotecan

View adult BNF View SPC online View childrens BNF
Non Formulary
Not Recommended

Aflibercept in combination with irinotecan and fluorouracil-based therapy is not recommended within its marketing authorisation for treatment metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen

Link  NICE TA307: Treating metastatic colorectal cancer
 
Irinotecan (Pegylated liposomal)  (Onivyde®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Not Recommended

Treatment of pancreatic cancer in adults

Link  NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
 
Regorafenib  (Stivarga® )

View adult BNF View SPC online View childrens BNF
Non Formulary
Not Recommended

Treatment of hepatocellular carcinoma in adults

Link  NICE TA514: Regorafenib for previously treated advanced hepatocellular carcinoma
 
Sorafenib  (Nexavar®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Not Recommended
Advanced hepatocellular cancer
Link  NICE TA474: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)
 
Cytotoxic Drug  Trabectedin  (Yondelis®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Not Recommended
In combination with pegylated liposomal doxorubicin for the treatment of patients with relapsed platinum-sensitive ovarian cancer
Link  NICE TA185: Soft tissue sarcoma - trabectedin
Link  NICE TA222- ovarian cancer
 
Cytotoxic Drug  Trastuzumab  (Herceptin®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Not Recommended
Not recommended for treating HER2 positive, unresectable locally advance or metastatic breast cancer previously treated with trastuzumab and a taxane
Link  NICE TA107: Breast cancer (early) - trastuzumab
Link  NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Link  NICE TA34: Breast cancer - trastuzumab
Link  NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab
 
Cytotoxic Drug  Vismodegib

View adult BNF View SPC online View childrens BNF
Non Formulary
Not Recommended

Treatment of basal cell carcinoma

Link  NICE TA489: Vismodegib for treating basal cell carcinoma
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Blueteq
High Cost Drug Approval System

Traffic Light Status Information

Status Description

Preferred

Clinicians are free to prescribe these drugs. They are regarded as cost effective choices which have evidence to support their use.  

Second Line

These drugs should only be prescribed in the scenarios described in the formulary after preferred drug(s) have been ruled out.  

Non Formulary

Non-formulary choice - the vast majority of a patient’s needs should be met by use of formulary preferred choices and second line options when appropriate. Therefore the Clinician should only use a non-formularly drug if this can be justified and it is recommended that all such instances are recorded in the patient record.  

Green SA

Specialist Advised – Specialists may simply advise a patient’s GP to initiate these drugs themselves after they have made an initial assessment. Note: SA drugs can be initiated by the specialist according to patient need and also depending on local commissioning arrangements which may mandate, through the contract between provider and commissioner, that all SA drugs are treated as SI.  

Green SI

Specialist Initiation - These drugs must be initiated, i.e. the first dose prescribed, by the specialist and then may be continued when appropriate by the patient’s GP following communication from the specialist.  

Amber SC

Shared Care - Responsibility for prescribing may be transferred from secondary to primary care with the agreement of an individual GP and when agreed shared care arrangements have been established. The specialist MUST stabilize the patient before asking for care to be transferred. Only specialists should initiate these drugs. Prescribing should be transferred to GPs according to an Shared Care Agreement [SCA]   

Red SO

Specialist Only - These drugs are deemed to be not appropriate for prescribing by GPs. Specialists should not ask GPs to prescribe these drugs.   

Black BL

Black Listed Medicines - These drugs are considered inappropriate for prescribing in Coventry & Warwickshire as they are either not cost-effective or of proven benefit or both.   

Not Recommended

Not Recommended - These are specialist drugs that are not recommended for use.  

netFormulary